| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ALBIREO PHARMA, INC. | Chief Medical Officer | Common Stock | 12,355 | $541,149 | $43.80 | 22 Oct 2021 | Direct |
| Fulcrum Therapeutics, Inc. | Chief Medical Officer | Stock Option (right to buy) | 400,000 | 18 Mar 2024 | Direct | ||
| Fulcrum Therapeutics, Inc. | Chief Medical Officer | No securities are beneficially owned | 0 | 18 Mar 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | 18 Mar 2024 | 1 | $0 | 4 | Chief Medical Officer | 20 Mar 2024, 16:15 |
| FULC | Fulcrum Therapeutics, Inc. | 18 Mar 2024 | 0 | $0 | 3 | Chief Medical Officer | 20 Mar 2024, 16:10 |
| ALBO | ALBIREO PHARMA, INC. | 22 Oct 2021 | 1 | -$2,739 | 4 | Chief Medical Officer | 25 Oct 2021, 18:41 |
| ALBO | ALBIREO PHARMA, INC. | 22 Jul 2021 | 1 | -$3,072 | 4 | Chief Medical Officer | 26 Jul 2021, 16:06 |